Analysts forecast that Guardant Health Inc (NASDAQ:GH) will announce sales of $24.57 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Guardant Health’s earnings, with the lowest sales estimate coming in at $20.99 million and the highest estimate coming in at $26.58 million. The business is expected to announce its next quarterly earnings report on Monday, February 18th.

According to Zacks, analysts expect that Guardant Health will report full year sales of $83.43 million for the current fiscal year, with estimates ranging from $82.50 million to $84.01 million. For the next year, analysts anticipate that the firm will post sales of $116.02 million, with estimates ranging from $111.69 million to $120.30 million. Zacks’ sales calculations are an average based on a survey of research analysts that follow Guardant Health.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Monday, November 19th. The company reported ($1.94) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($1.65). The company had revenue of $21.70 million for the quarter, compared to the consensus estimate of $17.44 million. The firm’s quarterly revenue was up 95.5% compared to the same quarter last year.

A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of Guardant Health in a research note on Monday, October 29th. They issued an “overweight” rating and a $42.00 price target for the company. Bank of America assumed coverage on shares of Guardant Health in a research note on Monday, October 29th. They issued a “neutral” rating and a $37.00 price target for the company. Cowen assumed coverage on shares of Guardant Health in a research note on Monday, October 29th. They issued an “outperform” rating for the company. William Blair initiated coverage on shares of Guardant Health in a research note on Monday, October 29th. They issued an “outperform” rating for the company. Finally, Leerink Swann reaffirmed an “outperform” rating on shares of Guardant Health in a research note on Monday, October 29th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Guardant Health presently has a consensus rating of “Buy” and an average price target of $39.50.

GH stock traded up $1.40 during trading on Friday, reaching $42.94. The company had a trading volume of 380,395 shares, compared to its average volume of 442,587. Guardant Health has a 52 week low of $27.04 and a 52 week high of $49.55.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.

Featured Story: Is a Roth IRA right for you?

Get a free copy of the Zacks research report on Guardant Health (GH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.